Richmol presented its core pyridine, pyrimidine and quinoline intermediates at the 74th API China & PHARMPACK & SINOPHEX, exchanging views with pharmaceutical companies and research institutions from China and abroad.
During the exhibition, our team discussed the R&D, process optimization, quality control and custom synthesis needs around high-value pharmaceutical intermediates, as well as the path from laboratory routes to scalable supply. Consistent batch quality and flexible delivery were among the topics most valued by visitors.
The exhibition gave Richmol a clearer view of industry demand for novel intermediates and process development, supporting future catalog expansion and customer collaboration.